<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="discussion" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Gastroenterol Hepatol (N Y)</journal-id><journal-id journal-id-type="iso-abbrev">Gastroenterol Hepatol (N Y)</journal-id><journal-id journal-id-type="pmc-domain-id">1204</journal-id><journal-id journal-id-type="pmc-domain">gasthep</journal-id><journal-id journal-id-type="publisher-id">GH</journal-id><journal-title-group><journal-title>Gastroenterology &amp; Hepatology</journal-title></journal-title-group><issn pub-type="ppub">1554-7914</issn><publisher><publisher-name>Millenium Medical Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11047149</article-id><article-id pub-id-type="pmcid-ver">PMC11047149.1</article-id><article-id pub-id-type="pmcaid">11047149</article-id><article-id pub-id-type="pmcaiid">11047149</article-id><article-id pub-id-type="pmid">38682122</article-id><article-id pub-id-type="other">GH_20_4_204</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Column</subject></subj-group></article-categories><title-group><article-title>Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sinh</surname><given-names initials="P">Preetika</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cross</surname><given-names initials="RK">Raymond K.</given-names></name><degrees>MD, MS</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><sup>1</sup>Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, Wisconsin</aff><aff id="aff2"><sup>2</sup>Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland</aff></contrib-group><author-notes><corresp>Corresponding author: Dr Preetika Sinh 8701 Watertown Plank Road Medical College of Wisconsin Milwaukee, WI 53226 Tel: (414) 955-6858 Fax: (414) 955-0037 E-mail: <email>psinh@mcw.edu</email></corresp><corresp><italic toggle="yes">Dr Sinh has no relevant conflicts of interest to disclose. Dr Cross has participated in consulting and advisory boards for AbbVie, Adiso, BMS, Fresenius Kabi, Fzata, Janssen, Magellan Health, Pfizer, Pharmacosmos, Samsung Bioepis, Sebela, and Takeda. He has a research grant with Janssen. He is also the Scientific Co-Director of the CorEvitas registry and is a member of the executive committee for the IBD Education Group.</italic></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2024</year></pub-date><volume>20</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">461115</issue-id><fpage>204</fpage><lpage>215</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-08 23:25:29.833"><day>08</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024, Gastro-Hep Communications, Inc.</copyright-statement><copyright-year>2024</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="GH_20_4_204.pdf"/><abstract><p>Patients with inflammatory bowel disease (IBD) have an increased risk of cardiovascular disease (CVD) such as myocardial infarction and stroke. CVD in patients with IBD might occur in those with younger age and active disease, which are not traditional risk factors of CVD. Atherosclerotic CVD (ASCVD) and IBD are both proinflammatory conditions, and the underlying chronic inflammation might drive ASCVD risk. Decreasing inflammation might reduce this risk; however, data are limited. IBD medications can increase or decrease ASCVD risk. There are no specific guidelines or modalities to assess ASCVD in IBD. Early detection and risk stratification strategies have been established in other chronic inflammatory disorders. This article discusses causes of CVD in IBD and strategies to modify the consequences.</p></abstract><kwd-group><kwd>Cardiovascular disease</kwd><kwd>inflammatory bowel disease</kwd><kwd>ulcerative colitis</kwd><kwd>Crohn&#8217;s disease</kwd><kwd>atherosclerosis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>